Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories australia pty ltd - strontium ranelate -

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril erbumine, quantity: 8 mg - tablet, uncoated - excipient ingredients: hydrophobic colloidal silica anhydrous; lactose monohydrate; chlorophyllin-copper complex; magnesium stearate; microcrystalline cellulose - the treatment of hypertension; and the treatment of heart failure. in such patients it is recommended that idaprex be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of idaprex has not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

New Zealand - English - Medsafe (Medicines Safety Authority)

servier laboratories nz ltd - irinotecan hydrochloride trihydrate 5 mg/ml (equiv 4.3 mg/ml irinotecan (anhydrous free base));   - concentrate for infusion - 43 mg/10ml - active: irinotecan hydrochloride trihydrate 5 mg/ml (equiv 4.3 mg/ml irinotecan (anhydrous free base))   excipient: 1,2-distearoyl-sn-glycero-3-phosphocholine cholesterol hepes n-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium chloride sucrosofate water for injection - treatment of metastatic adenocarcinoma of the pancreas in combination with 5-fluorouracil and folinic acid (leucovorin) in adult patients who have been previously treated with gemcitabine

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories australia pty ltd - pegaspargase -

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - ivosidenib, quantity: 250 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; magnesium stearate; sodium lauryl sulfate; titanium dioxide; hypromellose; triacetin; indigo carmine aluminium lake; hypromellose acetate succinate; lactose monohydrate - cholangiocarcinoma,tibsovo is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (idh1) r132 mutation after at least one prior line of systemic therapy.,acute myeloid leukaemia,tibsovo is indicated for the treatment of acute myeloid leukaemia (aml) that carries an idh1 r132 mutation:,? as monotherapy, or in combination with azacitidine, in newly diagnosed patients who are not eligible to receive intensive induction chemotherapy; or,? as monotherapy in patients whose aml is relapsed and/or refractory to prior therapy.

European Union - English - EMA (European Medicines Agency)

les laboratoires servier - pegaspargase - precursor cell lymphoblastic leukemia-lymphoma - antineoplastic agents, - oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (all) in paediatric patients from birth to 18 years, and adult patients.,

Ireland - English - HPRA (Health Products Regulatory Authority)

les laboratoires servier - perindopril tert-butylamine salt - tablets - 8 milligram

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories australia pty ltd - perindopril erbumine -

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories australia pty ltd - perindopril erbumine -

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories australia pty ltd - perindopril erbumine -